Roy Gomez
Overview
Explore the profile of Roy Gomez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
238
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weng W, Chan S, Gomez R, Wang F, Chou H, Lim J, et al.
J Neuromuscul Dis
. 2025 Feb;
12(1):22143602241297846.
PMID: 39973450
Background: Since 1970, advances in Duchenne muscular dystrophy (DMD) management have significantly extended the patients' life expectancy. However, DMD remains universally fatal. Objective: To understand the current DMD management standards...
2.
Gomez R, Khadilkar V, Shembalkar J, Chu D, Ko C, Wajnrajch M, et al.
J Pediatr Endocrinol Metab
. 2024 May;
37(6):525-531.
PMID: 38717038
Objectives: Somatrogon is a long-acting recombinant human growth hormone used to treat patients with paediatric growth hormone deficiency (pGHD). This global phase 3 study compared the efficacy and safety of...
3.
Baynam G, Gomez R, Jain R
Front Genet
. 2024 Apr;
15:1335768.
PMID: 38638122
Rare disease (RD) is a term used to describe numerous, heterogeneous diseases that are geographically disparate. Approximately 400 million people worldwide live with an RD equating to roughly 1 in...
4.
Angchaisuksiri P, Amurao-Abiera M, Chou S, Chewcharat P, Chozie N, Gomez R, et al.
Haemophilia
. 2024 Mar;
30(3):609-616.
PMID: 38523289
Background: The healthcare systems in Asia vary greatly due to the socio-economic and cultural diversities which impact haemophilia management. Methods: An advisory board meeting was conducted with experts in haemophilia...
5.
Giampietro A, Chiloiro S, Urbani C, Pivonello R, Carlsson M, Dassie F, et al.
Endocr Connect
. 2024 Jan;
13(3).
PMID: 38197875
Purpose: The aim of this study was to examine the probability of achieving acromegaly disease control according to several patient-, disease- and treatment-related factors longitudinally. Methods: We analyzed data from...
6.
Gomez R, Lamoureux R, Turner-Bowker D, Loftus J, Maghnie M, Miller B, et al.
Front Endocrinol (Lausanne)
. 2023 Nov;
14:1254424.
PMID: 37955005
Introduction: The standard of care for pediatric growth hormone deficiency (pGHD) is once-daily recombinant human growth hormone (rhGH). Somatrogon, a long-acting rhGH, requires less frequent, once-weekly, dosing. We describe physicians'...
7.
Maghnie M, Ranke M, Geffner M, Vlachopapadopoulou E, Ibanez L, Carlsson M, et al.
J Clin Endocrinol Metab
. 2023 Feb;
108(6):e356-e357.
PMID: 36721915
No abstract available.
8.
Maghnie M, Ranke M, Geffner M, Vlachopapadopoulou E, Ibanez L, Carlsson M, et al.
J Clin Endocrinol Metab
. 2022 Sep;
107(12):3287-3301.
PMID: 36102184
Context: The Kabi/Pfizer International Growth Database (KIGS) is a large, international database (1987-2012) of children treated with recombinant human growth hormone (rhGH) in real-world settings. Objective: This work aimed to...
9.
Horikawa R, Tanaka T, Hasegawa Y, Yorifuji T, Ng D, Rosenfeld R, et al.
Horm Res Paediatr
. 2022 Apr;
95(3):275-285.
PMID: 35417909
Introduction: Somatrogon is a long-acting recombinant human growth hormone being developed as a once-weekly treatment for children with growth hormone deficiency (GHD). The objective of this phase 3 study (NCT03874013)...
10.
Johannsson G, Touraine P, Feldt-Rasmussen U, Pico A, Vila G, Mattsson A, et al.
J Clin Endocrinol Metab
. 2022 Apr;
107(7):1906-1919.
PMID: 35368070
Context: Data on long-term safety of growth hormone (GH) replacement in adults with GH deficiency (GHD) are needed. Objective: We aimed to evaluate the safety of GH in the full...